Heldring Nina, Mäger Imre, Wood Matthew J A, Le Blanc Katarina, Andaloussi Samir E L
1 Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
2 Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Hum Gene Ther. 2015 Aug;26(8):506-17. doi: 10.1089/hum.2015.072. Epub 2015 Aug 3.
The therapeutic potential of mesenchymal stromal cells (MSCs) is evident by the number of new and ongoing trials targeting an impressive variety of conditions. In bone and cartilage repair, MSCs are expected to replace the damaged tissue, while in other therapies they modulate a therapeutic response by the secretion of bioactive molecules. MSCs possess a phenotypic plasticity and harbor an arsenal of bioactive molecules that can be released upon sensing signals in the local milieu either directly or packaged in extracellular vesicles (EVs). The reported paracrine effects comprise many of the important functions of MSCs, including supporting hematopoietic stem cells in the bone marrow, promoting angiogenesis, and modulating the immune system. The major drawback in MSC therapy is the incomplete understanding of cell fate following systemic administration as well as the mechanisms by which these cells correct disease. In this review we discuss what is known about MSC engraftment, hemocompatibility, and immunomodulation, as well as the potential of bringing the MSC-EV field toward a clinical translation.
间充质基质细胞(MSCs)的治疗潜力从针对各种令人瞩目的病症开展的新的和正在进行的试验数量中可见一斑。在骨和软骨修复中,间充质基质细胞有望替代受损组织,而在其他治疗中,它们通过分泌生物活性分子来调节治疗反应。间充质基质细胞具有表型可塑性,并拥有一系列生物活性分子,这些分子可在感知局部环境中的信号时直接释放,或包装在细胞外囊泡(EVs)中释放。所报道的旁分泌效应涵盖了间充质基质细胞的许多重要功能,包括支持骨髓中的造血干细胞、促进血管生成以及调节免疫系统。间充质基质细胞疗法的主要缺点是对全身给药后细胞命运以及这些细胞纠正疾病的机制了解不全面。在本综述中,我们讨论了关于间充质基质细胞植入、血液相容性和免疫调节的已知情况,以及将间充质基质细胞外囊泡领域推向临床转化的潜力。